James Chalmers, MBChB, PhD

In this video, the last in a 5-part series, panelists discuss their future outlook on bronchiectasis management.

In this video, the fourth in a 5-part series, panelists discuss who may benefit from brensocatib's approval.

In this video, the third in a 5-part series, panelists discuss data from the phase 3 ASPEN trial.

In this video, the second in a 5-part series, panelists discuss the recent FDA approval of brensocatib.

In this video, the first in a 5-part series, panelists discuss recent advancements in bronchiectasis management.

In this interview, Chalmers highlights the implications of his team’s subgroup analysis findings in the ASPEN trial, as well as unmet needs for non-cystic fibrosis bronchiectasis.

Chalmers discussed how brensocatib’s potential approval may transform the currently empty treatment landscape for bronchiectasis.